证券代码：688221 证券简称：前沿生物 公告编号：2026-003 前沿生物药业（南京）股份有限公司2025年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经财务部门初步测算，预计2025年度实现营业收入约14,000.00万元到14,500.00万元，同比增加 8.13%到11.99%，营业收入主要来自抗HIV创新药艾可宁?（通用名：艾博韦泰）、代理产品缬康韦? （盐酸缬更昔洛韦）及报告期内获批的远红外治疗贴（小沿易贴?）的销售收入。 2、经财务部门初步测算，预计2025年度归属于上市公司股东的净利润亏损约25,500.00万元到亏损 29,000.00万元，增加亏损约5,361.74万元到8,861.74万元，主要系2024年度处置子公司股权产生7,183.65 万元的投资收益，2025年度无该类投资收益所致；预计2025年度归属于上市公司股东的扣除非经常性损 益的净利润亏损约28,800. ...

此外，2025年度，公司预计实现营业收入约1.4亿元到1.45亿元，同比增加8.13%到11.99%，营业收入主 要来自抗HIV创新药艾可宁（通用名：艾博韦泰）、代理产品缬康韦（盐酸缬更昔洛韦）及报告期获批 的远红外治疗贴（小沿易贴）的销售收入。 前沿生物表示，本次净利增亏主要系2024年度处置子公司股权产生7183.65万元的投资收益，2025年度 无该类投资收益所致。 北京商报讯（记者 丁宁）1月30日晚间，前沿生物（688221）发布2025年业绩预告显示，经财务部门初 步测算，预计2025年归属净利润约-2.55亿元到-2.9亿元，同比增亏。 ...

Core Insights - The company reported a revenue of 103.37 million yuan for the first three quarters of 2025, representing a year-on-year growth of 12.80% [1] - In Q3 2025, the company achieved a revenue of 44.73 million yuan, with a quarter-on-quarter increase of 47.58%, primarily driven by the sales of its innovative HIV drug and the代理产品缬康韦 [1] - The company invested 83.87 million yuan in R&D during the first three quarters, accounting for 81.13% of its revenue [1] R&D Focus - The company is concentrating its R&D efforts on small nucleic acid drugs, while also advancing the development of long-acting anti-HIV drugs and high-end generic drugs [1] - Two small nucleic acid drugs, FB7013 and FB7011, with First-in-Class potential have been developed, with FB7013 completing GMP batch production and non-clinical studies proceeding as planned [1] - FB7011 has completed efficacy studies in a monkey model for IgA nephropathy [1] Product Development and Commercialization - The company is advancing the R&D of FB3002 and other chemical drug hot melt adhesive products, with its subsidiary obtaining a production license for FB3002 [2] - In the pain management sector, the company has initiated commercial production of two specifications of far-infrared therapeutic patches and is expanding its online marketing channels [2] - New institutional investors, including E Fund Medical Healthcare Mixed Securities Investment Fund and E Fund Taihe Growth Stock Pension Product, have entered the company's top ten shareholders list, holding 2.06% and 1.67% of shares respectively [2]